Is Onconetix going out of business?

Onconetix, Inc. (ONCO) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

Onconetix, Inc. (ONCO) scores 6 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: Shares dilution YoY: 195.56% (YoY)

Five questions, kept separate

Survival - Critical

3-6 mo of estimated runway from 2026-06-30, based on $5.9M of cash and short-term investments against $15.8M of annual burn. Adjusted shares outstanding increased 195.6% over the comparison year.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Reasonable

142.7% net-cash backing support a reasonable pre-commercial Valuation assessment.

Event risk - Critical event risk

Going-Concern Warning is the decisive filing event; one adverse event family is active. It appears across 2 scanned filings. Favorable events are shown separately and do not offset adverse risk.

What the rules read

• Shares dilution YoY: 195.56% (YoY)
• ROIC: -217.35%
• Interest coverage: -2038.4x
• Filing event risk: Going-Concern Warning (-8 pts)
• Debt / Equity: No financial debt (debt-free)
• Revenue growth YoY: -83.92% (YoY)
• Return on Assets: -85.43%
• Debt Maturity Runway: 0% long-term (Near-term refinancing risk)
• Price / Sales: 4.4x (see Valuation)
• Price / Earnings: Unprofitable (see Valuation)
• Operating leverage: -2821.4%
• Effective Tax Rate: 0.00% (loss-making)

Read from filings through 2026-08-13.

Price as of 2026-09-07.